LabGenius and Sanofi in new collaboration

UK-based LabGenius Therapeutics, a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimize potential therapeutic antibodies, has announced a second collaboration with French pharma major Sanofi (Euronext: SAN).

This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic Nanobody molecules to co-optimize proteins for therapeutically valuable properties.

The first deal between the parties - initiated in 2021 - is a multi-year collaboration in the area of inflammation that combined LabGenius’ capabilities in machine learning (ML), robotic automation and synthetic biology, with Sanofi’s expertise in the therapeutic development of Nanobody heavy chain variable domains.